


April 2026

Reaching the full potential of Gene Editing

 **International
Convention**
June 22-25 | San Diego



AlgenScribe, a versatile approach in gene editing





Improving the Efficiency and Quality of Gene Replacement

Module 1

Fostering HDR
X 12

Module 2

Inhibition of NHEJ
X 24



HDR: Homology Directed Repair
NHEJ: Non-Homologous End-Joining

A value-creating Gene Editing Platform

Gene Editing

Dynamic Market

CAGR: 30-40%

Market size by 2030

~\$25-\$35B

*Source: Precision
Biosciences*



Value Proposition

Addressing technological challenges:

- **Boosts Efficiency:** Dramatically increases HDR and gene replacement rates
- **Enhances Precision:** Minimizes off-target effects and nuclease-induced mutations
- **Full-Scale Flexibility:** Edits from single bases to multi-kilobase insertions
- **Versatile Utility:** Spans research, therapeutics, diagnostics, and bioproduction

Responding to identified needs:

- **Expansive:** Unlocks novel gene replacement programs
- **Flexible:** Targets multiple mutations within a single disease
- **Economical:** Higher yields with reduced synthetic DNA costs
- **Secure:** Maximizes safety by limiting genomic alterations
- **Non-viral:** Bypasses AAV-related delivery constraints.



<https://www.algenscribe.fr/>

ALGENSCRIBE

bpifrance
SERVING THE FUTURE

anr®
agence nationale
de la recherche

ers genomics
THE CRISPR
LICENSING
COMPANY

institut
imagine
GUÉRIR LES MALADIES GÉNÉTIQUES

**INCUBATEUR
PROVENCE
CÔTE D'AZUR**
INNOVER. ENTREPRENDRE

ME
di
CEN
PARIS
REGION



LA
FRENCH TECH
PARIS-SACLAY

Inserm
La science pour la santé
From science to health

**MAX
DELBRÜCK
CENTER**

EURObiomed

Spartners
by Servier & BioLabs

PSCC
PARIS SACLAY CANCER CLUSTER

**RÉGION
SUD**
PROVENCE
ALPES
CÔTE D'AZUR

france
biotech
biotech | medtech | e-santé | IA
LES ENTREPRENEURS DE LA HEALTHTECH

GenoTher
Gene Therapy Biocluster

GENOPOLE

Contact:

contact@algenscribe.com



AlgenScribe